Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Capital Expenditures (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Capital Expenditures data on record, last reported at $498000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 77.22% year-over-year to $498000.0; the TTM value through Sep 2025 reached $2.1 million, up 177.2%, while the annual FY2024 figure was $1.3 million, 108.79% up from the prior year.
  • Capital Expenditures reached $498000.0 in Q3 2025 per PLX's latest filing, up from $431000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $880000.0 in Q4 2024 and bottomed at -$272000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $249105.3, with a median of $281000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: plummeted 263.79% in 2023, then skyrocketed 1824.0% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $448000.0 in 2021, then tumbled by 160.71% to -$272000.0 in 2022, then soared by 232.72% to $361000.0 in 2023, then skyrocketed by 143.77% to $880000.0 in 2024, then crashed by 43.41% to $498000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $498000.0 in Q3 2025, $431000.0 in Q2 2025, and $306000.0 in Q1 2025.